Sean McClain, Absci CEO
January 7, 2022 10:39 AM EST
Deals
AI

Mer­ck revs up deal­mak­ing en­gine ahead of #JPM22, ink­ing col­lab­o­ra­tions with AI pro­tein de­sign play­er Ab­sci

Max Gelman

Senior Editor

In the year-plus since Roger Perl­mut­ter left his post lead­ing Mer­ck’s R&D ef­forts, the Big Phar­ma’s new lead­er­ship has con­tin­ued to pur­sue an ag­gres­sive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

NewAms­ter­dam aces Phase 3 tri­al, but in­vestors are skep­ti­cal

Post-Hoc: RFK vs. Vivek, and the fu­ture of US drug pol­i­cy

FDA up­dates la­bel of 33-year-old can­cer drug with new dose and warn­ing

When gen­er­a­tive AI meets the FDA: First dig­i­tal health ad­comm kicks off dis­cus­sion

Pfiz­er part­ners with two more Flag­ship biotechs on obe­si­ty, can­cer

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times